On August 22nd, Yaoming Bio held an interim results conference in Hong Kong and announced its half-year results until the end of June. In the first half of 2017, the revenue of Yaoming Biological was 654 million yuan, an increase of 59.5% year-on-year; the gross profit was about 264 million. Yuan, an increase of 41.6% year-on-year, but the gross profit margin decreased by 5 points to 40.4% compared with the same period of last year, and the net profit was about 92.2 million yuan, an increase of 9.9%. For the increase in revenue, Yao Ming Biology said that the main growth driver comes from the continuous growth of the number of customers and the strong growth of comprehensive projects; the company strengthens its marketing efforts, and has achieved excellent performance in China, the United States and Europe, and won with the company. More customers trust and expand market influence, and the company's market share is gradually increasing. As for the decline in gross profit margin, PharmaTech said that it was mainly due to the reduction of milestones in enjoying high profit margins. The new facilities in Wuxi Base were in trial operation, which led to an increase in materials and labor costs, as well as the depreciation of the US dollar against the RMB. According to the half-year interim results of Yaoming Bio, in the first half of the year, the earnings before IND recorded 448 million yuan, a year-on-year increase of 50.3%, accounting for 68.5% of the company's total revenue; the service fee after IND recorded a revenue of 206 million yuan, a year-on-year increase. 83.8%, accounting for 31.5% of the company's total revenue. As of June 30, the company has a total of 134 comprehensive projects, including IND pre-service projects, a total of 92 projects in the pre-clinical development stage, which is expected to last for about 2 years, with general income ranging from 4 million to 6 million US dollars. . The post-IND service project, currently in the early (stages I and II) clinical development phase, has 35 projects and is expected to last for three years with benefits ranging from $4 million to $6 million. There are 6 projects in the late stage (phase III) clinical development stage, which are expected to take 3-5 years, and the income ranges from 20 to 50 million US dollars. One project is already in commercial production and is expected to earn between $50 million and $100 million annually. Li Ming, chairman of Yaoming Biology, said that as of June 30, 2017, Yaoming Bio has cooperated with 12 of the world's top 20 pharmaceutical companies, with 151 customer service customers and uncompleted orders from 6800 in the same period last year. Ten thousand dollars has rapidly increased to 452 million US dollars, an increase of 564.7%. According to Chen Zhisheng, CEO of Yaoming Biological, the company will continue to adopt the strategy of “following the development of drug molecules to expand its business†to achieve strong revenue growth. In the first half of 2017, the company had 134 comprehensive projects that required the company to provide services in different biological development processes, an increase of 78.7% over the same period last year (75 projects in the first half of 2016). Through the operation of these projects, high productivity, and fast turnaround time, customers have left a good reputation. Pharmacopoeia was officially listed on the Hong Kong Stock Exchange on June 13, 2017. It has three operating bases in Wuxi, Shanghai and Suzhou, and operates through six subsidiaries, including Wuxi Biotechnology, Suzhou Testing, and Shanghai Biotechnology. , HK Biologics, US Biologics and UK Biologics. According to the previously published prospectus, in 2014-2016, Yaoming Biotech achieved operating income of 332 million yuan, 557 million yuan and 989 million yuan respectively, with net profit of 41.98 million yuan, 44.51 million yuan and 141 million yuan respectively. At this stage, Yaoming Bio is building the world's largest commercial production facility for biologics using disposable bioreactors at Wuxi Base, with a planned production capacity of 30,000 liters, and a new clinical production facility with a planned capacity of 7,000 liters at the Shanghai base. Customer demand for commercial production of biologics and clinical development of biologics. At present, Yaoming Bio has completed the construction of some new facilities in Wuxi Base. These facilities are currently in trial operation. It is expected that Wuxi's new facilities will be put into operation before the end of 2017. In February of this year, Yaoming Bio began to build new facilities at the Shanghai base, and the new facility is expected to be operational in the second quarter of 2018.
Fresh apple is selected, trimmed, cut and dehydrated.
Apple dice,rings,Freeze-dried apples,dehydrated apples,freeze-dried diced apples Xinghua Lvwei Foods Co.,Ltd , https://www.lvweifoods.com
